Rxdatascience India Profile
Key Indicators
- Authorised Capital ₹ 9.60 M
- Paid Up Capital ₹ 9.58 M
- Company Age 7 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 149.16%
- Profit Growth 228.39%
- Ebitda 192.06%
- Net Worth 140.71%
- Total Assets 81.68%
About Rxdatascience India
Rxdatascience India Private Limited (RIPL) is a Private Limited Indian Non-Government Company incorporated in India on 22 August 2017 (Seven years and five months 12 days old ). Its registered office is in Salem, Tamil Nadu, India.
The Corporate was formerly known as Rx Data Science Pharma Software Solution India Private Limited. The Company is engaged in the Information Technology Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 9.60 M and a paid-up capital of Rs 9.58 M, as per Ministry of Corporate Affairs (MCA) records.
Company Details
-
Location
Salem, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74999TZ2017PTC029368
-
Company No.
029368
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
22 Aug 2017
-
Date of AGM
26 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Coimbatore
Industry
Who are the key members and board of directors at Rxdatascience India?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kapil Kapoor
|
Director | 08-Feb-2022 | Current |
Imene Charpentier
|
Director | 08-Feb-2022 | Current |
|
Vikas Sachdeva
|
Director | 23-May-2023 | Current |
Financial Performance of Rxdatascience India.
Rxdatascience India Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 149.16% increase. The company also saw a substantial improvement in profitability, with a 228.39% increase in profit. The company's net worth Soared by an impressive increase of 140.71%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rxdatascience India?
In 2019, Rxdatascience India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Syneos Health India Private LimitedKapil Kapoor and Imene Charpentier are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rxdatascience India?
Rxdatascience India has a workforce of 151 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rxdatascience India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rxdatascience India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
